

I. AMENDMENTS

In the Specification:

Please replace the paragraph beginning at page 3 line 26 with the following rewritten paragraph:

--One aspect of the present invention features compositions suppressing local inflammatory reactions. The compositions comprise a lactoferrin and a pharmaceutically acceptable carrier. These compositions may alternatively, or in addition, include functional analogs or functional fragments of lactoferrin which exhibit the desired inhibitory activities on the locally induced TNF- α -dependent inflammation.--

Please replace the paragraph beginning at page 38 line 24 with the following rewritten paragraph:

--Figure 5 shows the inhibitory effect of lactoferrin on oxazolone induced dendritic cell accumulation in draining lymph nodes when lactoferrin is applied topically to the skin surface.—

In the Claims:

Please amend claims 5 and 21 as follows:

5. (Twice Amended) A method of treating an allergen-induced inflammatory disorder in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of a lactoferrin product, said amount being sufficient to reduce inflammation-induced Langerhans cell migration or accumulation of dendritic cells in lymph nodes.